Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Update

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 53,200 shares, a decline of 56.6% from the February 28th total of 122,600 shares. Currently, 3.3% of the shares of the company are short sold. Based on an average daily trading volume, of 395,000 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptose Biosciences stock. Bleichroeder LP acquired a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,500,000 shares of the biotechnology company’s stock, valued at approximately $563,000. Bleichroeder LP owned approximately 4.15% of Aptose Biosciences as of its most recent SEC filing. 26.62% of the stock is currently owned by institutional investors.

Aptose Biosciences Price Performance

Shares of NASDAQ:APTO opened at $3.32 on Friday. The company has a market capitalization of $7.11 million, a P/E ratio of -1.12 and a beta of 1.14. Aptose Biosciences has a 1-year low of $2.39 and a 1-year high of $51.61. The firm’s 50 day simple moving average is $4.57 and its two-hundred day simple moving average is $7.54.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. StockNews.com started coverage on shares of Aptose Biosciences in a research report on Thursday. They issued a “sell” rating on the stock. HC Wainwright raised their target price on Aptose Biosciences from $2.00 to $6.00 and gave the stock a “buy” rating in a report on Friday. Finally, Alliance Global Partners raised Aptose Biosciences to a “strong-buy” rating in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $112.00.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.